SCHEMBL4143597

SCHEMBL4143597

O=C(NC1CCCC1O)c1[nH]c2ncc(NS(=O)(=O)c3ccc(OC(F)(F)F)cc3)cc2c1-c1cccs1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.39
HTR6 P50406 3/20 0.38
TP53 P04637 1/20 0.36
SERPINE1 P05121 1/20 0.36
SCN3A Q9NY46 1/20 0.35
NAMPT P43490 1/20 0.34
FFAR4 Q5NUL3 1/20 0.34
HCRTR1 O43613 1/20 0.34
DRD4 P21917 2/20 0.34
HTR2A P28223 2/20 0.34
DDB1 Q16531 1/20 0.34
CRBN Q96SW2 1/20 0.34
DRD2 P14416 1/20 0.34
ROCK2 O75116 1/20 0.34
ROCK1 Q13464 1/20 0.34
KIT P10721 1/20 0.34
LOXL2 Q9Y4K0 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4143601 1.00 CNR1 (0.39) CNR1HTR6TP53SERPINE1SCN3A
SCHEMBL4138419 0.88 SERPINE1 (0.45) CNR1HTR6TP53SERPINE1NAMPT
SCHEMBL4138421 0.88 SERPINE1 (0.45) CNR1HTR6TP53SERPINE1NAMPT
SCHEMBL4133870 0.88 CNR1 (0.41) CNR1HTR6TP53SERPINE1SCN3A
SCHEMBL4133869 0.88 CNR1 (0.41) CNR1HTR6TP53SERPINE1SCN3A
SCHEMBL4142664 0.88 BRD4 (0.37) HTR6SERPINE1NAMPT
SCHEMBL4142667 0.88 BRD4 (0.37) HTR6SERPINE1NAMPT
SCHEMBL4135797 0.86 CNR1 (0.39) CNR1HTR6SERPINE1NAMPTFFAR4
SCHEMBL4135800 0.86 CNR1 (0.39) CNR1HTR6SERPINE1NAMPTFFAR4
SCHEMBL4071552 0.85 SERPINE1 (0.44) TP53SERPINE1SCN3AFFAR4ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090098189-A1 AZAINDOLES AS INHIBITORS OF SOLUBLE ADENYLATE CYCLASE BAYER SCHERING PHARMA AG (DE) 2009-04-16 US claimed
US-20090098189-A1 AZAINDOLES AS INHIBITORS OF SOLUBLE ADENYLATE CYCLASE BAYER SCHERING PHARMA AG (DE) 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090098189-A1 AZAINDOLES AS INHIBITORS OF SOLUBLE ADENYLATE CYCLASE ADCY1, ADCY5, ADCY2 CNR1 1177/4885HTR6 1293/4885TP53 3206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.